NCT02131584 2026-04-16
Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT03610971 2026-04-02
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03722407 2026-04-02
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03286530 2026-03-27
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03514069 2026-02-19
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02876302 2026-02-04
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03120624 2026-02-04
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
Mayo Clinic
Phase 1 Active not recruiting
NCT04217356 2026-01-26
ALLO-BAT
University Health Network, Toronto
Active not recruiting
NCT06768476 2026-01-16
AML
University of Pennsylvania
Phase 1 Active not recruiting
NCT03117751 2025-12-05
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2/3 Active not recruiting
NCT03674047 2025-11-10
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT02494882 2025-07-02
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT02577926 2025-06-10
Ruxo-BEAT
RWTH Aachen University
Phase 2 Active not recruiting